Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSBR-1290 Phase 1b/2a in Overweight/Obese Adults and T2DM
NCT05762471Phase 2Completed
- Sponsor
- Gasherbrum Bio
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aleniglipron in Overweight, obesity and type 2 diabetes mellitus (T2DM) (5 cohorts), sponsored by Gasherbrum Bio. Primary endpoint: Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG at 42 days. Started Jan 2023; status: completed.
02
Drugs
aleniglipron
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05762471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762471.